Measurement of Cardiopulmonary Variables After Acute Exposure to High Altitude
Launched by CENTRO CARDIOLOGICO MONZINO · Mar 3, 2023
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how high altitude affects the heart and lungs, particularly for people who may already have heart or breathing issues. When you go to a high altitude, like Punta Helbronner, which is over 3,400 meters above sea level, there is less oxygen in the air. This can put a strain on your cardiovascular system, potentially leading to serious health risks such as heart attacks or strokes. The researchers want to gather information from a large number of people who visit this high-altitude location to understand better how their heart rates, blood pressure, and oxygen levels change when they are exposed to such conditions.
To participate in this study, you need to be at least 18 years old. Participants will complete a short health questionnaire and then use a special device that will measure various health indicators like heart rate and blood pressure. The process is easy and guided, and your information will be kept private. This research aims to build a unique database that can help identify individuals who may be at greater risk of health problems when exposed to high altitudes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- Exclusion Criteria:
- • Age \< 18 years
About Centro Cardiologico Monzino
Centro Cardiologico Monzino (CCM) is a leading cardiovascular research and treatment facility based in Milan, Italy, renowned for its commitment to advancing cardiac care through innovative clinical trials and cutting-edge research. Affiliated with the Italian Ministry of Health, CCM specializes in a comprehensive range of cardiovascular services, including diagnostics, interventional cardiology, and rehabilitation. The institution is dedicated to fostering collaboration among healthcare professionals, researchers, and patients to enhance the understanding of cardiovascular diseases and improve therapeutic outcomes. With a focus on translating scientific discoveries into clinical practice, CCM plays a pivotal role in shaping the future of cardiovascular medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Courmayeur, Aosta, Italy
Patients applied
Trial Officials
Piergiuseppe Agostoni, Prof
Principal Investigator
Centro Cardiologico Monzino
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials